Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Associated Therapies: -

Clinical Trials

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Biphenotypic Leukemia
Acute Undifferentiated Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Refractory Childhood Acute Lymphoblastic Leukemia
Acute Leukemia of Ambiguous Lineage
Adult Acute Myeloid Leukemia in Remission
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total-Body Irradiation

First Posted Date: 2013-05-21

Last Posted Date: 2024-03-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01858740

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

T&B Depletion Non Malignant

Phase 2

Conditions: Graft Versus Host Disease

Interventions: Biological: polyclonal antibody
Drug: Treosulfan
Drug: Rituximab
Drug: Fludarabine
Drug: Thiotepa
Drug: Cyclosporine A
Drug: Methotrexate

First Posted Date: 2013-03-14

Last Posted Date: 2013-03-14

Lead Sponsor: Franco Locatelli

Target Recruit Count: 130

Registration Number: NCT01810926

Locations: 🇮🇹
San Raffaele Scientific Institute, Milano, Italy
🇮🇹
University of Cagliari, Cagliari, Italy
🇮🇹
University of Milano-Bicocca San Gerardo Hospital, Monza, Italy

and more 1 locations

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Radiation: Total Lymphoid Irradiation
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Thiotepa
Drug: Melphalan
Biological: HPC,A Infusion
Biological: TC-NK Infusion
Biological: G-CSF
Drug: Mesna
Device: CliniMACS
Drug: Mycophenolate mofetil

First Posted Date: 2013-03-08

Last Posted Date: 2022-10-31

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 82

Registration Number: NCT01807611

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

Phase 2

Conditions: B-cell Lymphoma Refractory

Interventions: Drug: Thiotepa
Drug: Busulfan
Drug: Fludarabin
Procedure: transplant (HCT)
Radiation: Cytoreduction
Drug: Immunosuppression
Drug: Cyclosporine
Drug: Methotrexate
Drug: ATG
Procedure: Collection and infusions of Donor PBSC

First Posted Date: 2013-02-07

Last Posted Date: 2014-07-08

Lead Sponsor: Azienda Ospedaliera San Giovanni Battista

Target Recruit Count: 42

Registration Number: NCT01786018

Locations: 🇮🇹
Città della Salute e della Scienza di Torino, Torino, Italy

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma
Non-Hodgkin's Lymphoma
Leukemia
Myelodysplastic Syndrome

Interventions: Biological: Palifermin
Biological: Lupron
Procedure: peripheral blood stem cell transplantation
Radiation: Total-Body Irradiation (TBI)
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Degarelix

First Posted Date: 2012-12-11

Last Posted Date: 2024-01-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT01746849

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Chronic Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Cyclophosphamide
Drug: Cyclosporine
Biological: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Drug: Thiotepa
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2012-09-21

Last Posted Date: 2021-07-06

Lead Sponsor: Nohla Therapeutics, Inc.

Target Recruit Count: 163

Registration Number: NCT01690520

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 5 locations

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Not Applicable

Terminated

Conditions: Acute Leukemia
Chronic Leukemia
Myelodysplastic Syndrome
Non-Hodgkins Lymphoma

Interventions: Radiation: total-body irradiation (TBI)
Drug: thiotepa
Drug: fludarabine phosphate
Drug: melphalan
Biological: anti-thymocyte globulin
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2012-05-15

Last Posted Date: 2018-08-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT01598025

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: thiotepa
Procedure: stem cell transplant
Drug: G-CSF

First Posted Date: 2012-01-18

Last Posted Date: 2021-08-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 113

Registration Number: NCT01511562

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 123 locations